Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study

Fábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, Catarina Ramos, Catarina Bernardo, Cláudia Brito, Alexandra Mayer-da-Silva, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana Miranda, António Lourenço

Open source

DOI
10.1016/j.breast.2022.02.005
Published
2022-04
Container
The Breast
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2022.02.005,
  title = {Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study},
  author = {Fábio Cardoso Borges and Filipa Alves da Costa and Adriana Ramos and Catarina Ramos and Catarina Bernardo and Cláudia Brito and Alexandra Mayer-da-Silva and Cláudia Furtado and Arlindo R. Ferreira and Diogo Martins-Branco and Ana Miranda and António Lourenço},
  year = {2022},
  journal = {The Breast},
  doi = {10.1016/j.breast.2022.02.005},
  url = {https://doi.org/10.1016/j.breast.2022.02.005}
}

RIS

TY  - JOUR
TI  - Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
AU  - Fábio Cardoso Borges
AU  - Filipa Alves da Costa
AU  - Adriana Ramos
AU  - Catarina Ramos
AU  - Catarina Bernardo
AU  - Cláudia Brito
AU  - Alexandra Mayer-da-Silva
AU  - Cláudia Furtado
AU  - Arlindo R. Ferreira
AU  - Diogo Martins-Branco
AU  - Ana Miranda
AU  - António Lourenço
PY  - 2022
JO  - The Breast
DO  - 10.1016/j.breast.2022.02.005
UR  - https://doi.org/10.1016/j.breast.2022.02.005
ER  - 

APA

Borges, F. C., Costa, F. A. D., Ramos, A., Ramos, C., Bernardo, C., Brito, C., Mayer-da-Silva, A., Furtado, C., Ferreira, A. R., Martins-Branco, D., Miranda, A., & Lourenço, A. (2022). Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study. The Breast. https://doi.org/10.1016/j.breast.2022.02.005

Source records